Blueprint的Ayvakit成为美国获批治疗罕见胃肠道间质瘤突变的靶向疗法

2020-01-10 不详 MedSci原创

FDA周四宣布已批准Blueprint Medicines的Ayvakit(avapritinib)治疗患有PDGFR-α外显子18突变的不可切除或转移性胃肠道间质瘤(GIST)成年患者。


FDA周四宣布已批准Blueprint Medicines的Ayvakit(avapritinib)治疗患有PDGFR-α外显子18突变的不可切除或转移性肠道间质瘤(GIST)成年患者。

FDA药品评估与研究中心肿瘤病学办公室代理主任Richard Pazdur说,带有PDGFR-alpha外显子18突变的GIST患者"对标准疗法无反应,"但Ayvakit获批将作为第一种专门用于治疗具有该突变的GIST患者。

该决定基于NAVIGATOR试验的结果,试验涉及43名携带PDGFR-alpha外显子18突变的GIST患者,包括38名PDGFR-alpha D842V突变的GIST患者。参与者每天口服一次Ayvakit,直到疾病进展或出现不可接受的毒性。

结果显示总体响应率(ORR)为84%,其中7%达到完全响应,而77%达到部分响应。在具有PDGFR-αD842V突变的患者亚组中,ORR为89%,完全缓解和部分缓解分别为8%和82%。FDA指出,虽然未达到反应的中位持续时间,但有61%的外显子18突变的应答患者应答时间持续了六个月或更长时间。

Blueprint首席运营官Kate Haviland指出:"我们不仅在缩小肿瘤方面发挥了重要作用,而且还使他们在很长一段时间内保持无疾病进展。"

该公司计划一周内在美国提供Ayvakit,该药物先前被FDA授予了突破性疗法和孤儿药称号。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1780389, encodeId=c7551e8038984, content=<a href='/topic/show?id=bafd3539de' target=_blank style='color:#2F92EE;'>#Blueprint#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3539, encryptionId=bafd3539de, topicName=Blueprint)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4902500082, createdName=1249883fm12暂无昵称, createdTime=Thu Jan 16 15:57:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780263, encodeId=ae3f1e8026309, content=<a href='/topic/show?id=e7ea30e206' target=_blank style='color:#2F92EE;'>#Ayvakit#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3072, encryptionId=e7ea30e206, topicName=Ayvakit)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Tue Sep 01 04:57:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923730, encodeId=9f6a1923e30d2, content=<a href='/topic/show?id=093b353eed' target=_blank style='color:#2F92EE;'>#blue#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3537, encryptionId=093b353eed, topicName=blue)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Thu Mar 26 17:57:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807401, encodeId=834f180e4014c, content=<a href='/topic/show?id=bbbfe98944d' target=_blank style='color:#2F92EE;'>#美国获批#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79894, encryptionId=bbbfe98944d, topicName=美国获批)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Dec 04 00:57:00 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341131, encodeId=bb801341131ef, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2235, encryptionId=b97e223562, topicName=AKI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346299, encodeId=3234134629909, content=<a href='/topic/show?id=339e8332035' target=_blank style='color:#2F92EE;'>#胃肠道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83320, encryptionId=339e8332035, topicName=胃肠道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378547, encodeId=e25d13e85471a, content=<a href='/topic/show?id=2cf09992871' target=_blank style='color:#2F92EE;'>#靶向疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99928, encryptionId=2cf09992871, topicName=靶向疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b676418, createdName=yanghan, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426027, encodeId=b460142602e01, content=<a href='/topic/show?id=02fe9e30227' target=_blank style='color:#2F92EE;'>#间质瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97302, encryptionId=02fe9e30227, topicName=间质瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ede4029724, createdName=zhty5338, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467511, encodeId=6265146e511e5, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585480, encodeId=2709158548033, content=<a href='/topic/show?id=f19310515b9' target=_blank style='color:#2F92EE;'>#KIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10515, encryptionId=f19310515b9, topicName=KIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8ff17204571, createdName=shuangle, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1780389, encodeId=c7551e8038984, content=<a href='/topic/show?id=bafd3539de' target=_blank style='color:#2F92EE;'>#Blueprint#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3539, encryptionId=bafd3539de, topicName=Blueprint)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4902500082, createdName=1249883fm12暂无昵称, createdTime=Thu Jan 16 15:57:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780263, encodeId=ae3f1e8026309, content=<a href='/topic/show?id=e7ea30e206' target=_blank style='color:#2F92EE;'>#Ayvakit#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3072, encryptionId=e7ea30e206, topicName=Ayvakit)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Tue Sep 01 04:57:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923730, encodeId=9f6a1923e30d2, content=<a href='/topic/show?id=093b353eed' target=_blank style='color:#2F92EE;'>#blue#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3537, encryptionId=093b353eed, topicName=blue)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Thu Mar 26 17:57:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807401, encodeId=834f180e4014c, content=<a href='/topic/show?id=bbbfe98944d' target=_blank style='color:#2F92EE;'>#美国获批#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79894, encryptionId=bbbfe98944d, topicName=美国获批)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Dec 04 00:57:00 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341131, encodeId=bb801341131ef, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2235, encryptionId=b97e223562, topicName=AKI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346299, encodeId=3234134629909, content=<a href='/topic/show?id=339e8332035' target=_blank style='color:#2F92EE;'>#胃肠道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83320, encryptionId=339e8332035, topicName=胃肠道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378547, encodeId=e25d13e85471a, content=<a href='/topic/show?id=2cf09992871' target=_blank style='color:#2F92EE;'>#靶向疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99928, encryptionId=2cf09992871, topicName=靶向疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b676418, createdName=yanghan, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426027, encodeId=b460142602e01, content=<a href='/topic/show?id=02fe9e30227' target=_blank style='color:#2F92EE;'>#间质瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97302, encryptionId=02fe9e30227, topicName=间质瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ede4029724, createdName=zhty5338, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467511, encodeId=6265146e511e5, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585480, encodeId=2709158548033, content=<a href='/topic/show?id=f19310515b9' target=_blank style='color:#2F92EE;'>#KIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10515, encryptionId=f19310515b9, topicName=KIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8ff17204571, createdName=shuangle, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=)]
    2020-09-01 周虎
  3. [GetPortalCommentsPageByObjectIdResponse(id=1780389, encodeId=c7551e8038984, content=<a href='/topic/show?id=bafd3539de' target=_blank style='color:#2F92EE;'>#Blueprint#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3539, encryptionId=bafd3539de, topicName=Blueprint)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4902500082, createdName=1249883fm12暂无昵称, createdTime=Thu Jan 16 15:57:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780263, encodeId=ae3f1e8026309, content=<a href='/topic/show?id=e7ea30e206' target=_blank style='color:#2F92EE;'>#Ayvakit#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3072, encryptionId=e7ea30e206, topicName=Ayvakit)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Tue Sep 01 04:57:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923730, encodeId=9f6a1923e30d2, content=<a href='/topic/show?id=093b353eed' target=_blank style='color:#2F92EE;'>#blue#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3537, encryptionId=093b353eed, topicName=blue)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Thu Mar 26 17:57:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807401, encodeId=834f180e4014c, content=<a href='/topic/show?id=bbbfe98944d' target=_blank style='color:#2F92EE;'>#美国获批#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79894, encryptionId=bbbfe98944d, topicName=美国获批)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Dec 04 00:57:00 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341131, encodeId=bb801341131ef, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2235, encryptionId=b97e223562, topicName=AKI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346299, encodeId=3234134629909, content=<a href='/topic/show?id=339e8332035' target=_blank style='color:#2F92EE;'>#胃肠道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83320, encryptionId=339e8332035, topicName=胃肠道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378547, encodeId=e25d13e85471a, content=<a href='/topic/show?id=2cf09992871' target=_blank style='color:#2F92EE;'>#靶向疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99928, encryptionId=2cf09992871, topicName=靶向疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b676418, createdName=yanghan, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426027, encodeId=b460142602e01, content=<a href='/topic/show?id=02fe9e30227' target=_blank style='color:#2F92EE;'>#间质瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97302, encryptionId=02fe9e30227, topicName=间质瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ede4029724, createdName=zhty5338, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467511, encodeId=6265146e511e5, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585480, encodeId=2709158548033, content=<a href='/topic/show?id=f19310515b9' target=_blank style='color:#2F92EE;'>#KIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10515, encryptionId=f19310515b9, topicName=KIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8ff17204571, createdName=shuangle, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1780389, encodeId=c7551e8038984, content=<a href='/topic/show?id=bafd3539de' target=_blank style='color:#2F92EE;'>#Blueprint#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3539, encryptionId=bafd3539de, topicName=Blueprint)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4902500082, createdName=1249883fm12暂无昵称, createdTime=Thu Jan 16 15:57:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780263, encodeId=ae3f1e8026309, content=<a href='/topic/show?id=e7ea30e206' target=_blank style='color:#2F92EE;'>#Ayvakit#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3072, encryptionId=e7ea30e206, topicName=Ayvakit)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Tue Sep 01 04:57:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923730, encodeId=9f6a1923e30d2, content=<a href='/topic/show?id=093b353eed' target=_blank style='color:#2F92EE;'>#blue#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3537, encryptionId=093b353eed, topicName=blue)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Thu Mar 26 17:57:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807401, encodeId=834f180e4014c, content=<a href='/topic/show?id=bbbfe98944d' target=_blank style='color:#2F92EE;'>#美国获批#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79894, encryptionId=bbbfe98944d, topicName=美国获批)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Dec 04 00:57:00 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341131, encodeId=bb801341131ef, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2235, encryptionId=b97e223562, topicName=AKI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346299, encodeId=3234134629909, content=<a href='/topic/show?id=339e8332035' target=_blank style='color:#2F92EE;'>#胃肠道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83320, encryptionId=339e8332035, topicName=胃肠道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378547, encodeId=e25d13e85471a, content=<a href='/topic/show?id=2cf09992871' target=_blank style='color:#2F92EE;'>#靶向疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99928, encryptionId=2cf09992871, topicName=靶向疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b676418, createdName=yanghan, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426027, encodeId=b460142602e01, content=<a href='/topic/show?id=02fe9e30227' target=_blank style='color:#2F92EE;'>#间质瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97302, encryptionId=02fe9e30227, topicName=间质瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ede4029724, createdName=zhty5338, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467511, encodeId=6265146e511e5, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585480, encodeId=2709158548033, content=<a href='/topic/show?id=f19310515b9' target=_blank style='color:#2F92EE;'>#KIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10515, encryptionId=f19310515b9, topicName=KIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8ff17204571, createdName=shuangle, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1780389, encodeId=c7551e8038984, content=<a href='/topic/show?id=bafd3539de' target=_blank style='color:#2F92EE;'>#Blueprint#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3539, encryptionId=bafd3539de, topicName=Blueprint)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4902500082, createdName=1249883fm12暂无昵称, createdTime=Thu Jan 16 15:57:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780263, encodeId=ae3f1e8026309, content=<a href='/topic/show?id=e7ea30e206' target=_blank style='color:#2F92EE;'>#Ayvakit#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3072, encryptionId=e7ea30e206, topicName=Ayvakit)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Tue Sep 01 04:57:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923730, encodeId=9f6a1923e30d2, content=<a href='/topic/show?id=093b353eed' target=_blank style='color:#2F92EE;'>#blue#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3537, encryptionId=093b353eed, topicName=blue)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Thu Mar 26 17:57:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807401, encodeId=834f180e4014c, content=<a href='/topic/show?id=bbbfe98944d' target=_blank style='color:#2F92EE;'>#美国获批#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79894, encryptionId=bbbfe98944d, topicName=美国获批)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Dec 04 00:57:00 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341131, encodeId=bb801341131ef, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2235, encryptionId=b97e223562, topicName=AKI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346299, encodeId=3234134629909, content=<a href='/topic/show?id=339e8332035' target=_blank style='color:#2F92EE;'>#胃肠道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83320, encryptionId=339e8332035, topicName=胃肠道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378547, encodeId=e25d13e85471a, content=<a href='/topic/show?id=2cf09992871' target=_blank style='color:#2F92EE;'>#靶向疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99928, encryptionId=2cf09992871, topicName=靶向疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b676418, createdName=yanghan, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426027, encodeId=b460142602e01, content=<a href='/topic/show?id=02fe9e30227' target=_blank style='color:#2F92EE;'>#间质瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97302, encryptionId=02fe9e30227, topicName=间质瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ede4029724, createdName=zhty5338, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467511, encodeId=6265146e511e5, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585480, encodeId=2709158548033, content=<a href='/topic/show?id=f19310515b9' target=_blank style='color:#2F92EE;'>#KIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10515, encryptionId=f19310515b9, topicName=KIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8ff17204571, createdName=shuangle, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1780389, encodeId=c7551e8038984, content=<a href='/topic/show?id=bafd3539de' target=_blank style='color:#2F92EE;'>#Blueprint#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3539, encryptionId=bafd3539de, topicName=Blueprint)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4902500082, createdName=1249883fm12暂无昵称, createdTime=Thu Jan 16 15:57:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780263, encodeId=ae3f1e8026309, content=<a href='/topic/show?id=e7ea30e206' target=_blank style='color:#2F92EE;'>#Ayvakit#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3072, encryptionId=e7ea30e206, topicName=Ayvakit)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Tue Sep 01 04:57:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923730, encodeId=9f6a1923e30d2, content=<a href='/topic/show?id=093b353eed' target=_blank style='color:#2F92EE;'>#blue#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3537, encryptionId=093b353eed, topicName=blue)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Thu Mar 26 17:57:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807401, encodeId=834f180e4014c, content=<a href='/topic/show?id=bbbfe98944d' target=_blank style='color:#2F92EE;'>#美国获批#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79894, encryptionId=bbbfe98944d, topicName=美国获批)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Dec 04 00:57:00 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341131, encodeId=bb801341131ef, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2235, encryptionId=b97e223562, topicName=AKI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346299, encodeId=3234134629909, content=<a href='/topic/show?id=339e8332035' target=_blank style='color:#2F92EE;'>#胃肠道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83320, encryptionId=339e8332035, topicName=胃肠道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378547, encodeId=e25d13e85471a, content=<a href='/topic/show?id=2cf09992871' target=_blank style='color:#2F92EE;'>#靶向疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99928, encryptionId=2cf09992871, topicName=靶向疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b676418, createdName=yanghan, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426027, encodeId=b460142602e01, content=<a href='/topic/show?id=02fe9e30227' target=_blank style='color:#2F92EE;'>#间质瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97302, encryptionId=02fe9e30227, topicName=间质瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ede4029724, createdName=zhty5338, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467511, encodeId=6265146e511e5, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585480, encodeId=2709158548033, content=<a href='/topic/show?id=f19310515b9' target=_blank style='color:#2F92EE;'>#KIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10515, encryptionId=f19310515b9, topicName=KIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8ff17204571, createdName=shuangle, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=)]
    2020-01-12 liao1619
  7. [GetPortalCommentsPageByObjectIdResponse(id=1780389, encodeId=c7551e8038984, content=<a href='/topic/show?id=bafd3539de' target=_blank style='color:#2F92EE;'>#Blueprint#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3539, encryptionId=bafd3539de, topicName=Blueprint)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4902500082, createdName=1249883fm12暂无昵称, createdTime=Thu Jan 16 15:57:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780263, encodeId=ae3f1e8026309, content=<a href='/topic/show?id=e7ea30e206' target=_blank style='color:#2F92EE;'>#Ayvakit#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3072, encryptionId=e7ea30e206, topicName=Ayvakit)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Tue Sep 01 04:57:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923730, encodeId=9f6a1923e30d2, content=<a href='/topic/show?id=093b353eed' target=_blank style='color:#2F92EE;'>#blue#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3537, encryptionId=093b353eed, topicName=blue)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Thu Mar 26 17:57:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807401, encodeId=834f180e4014c, content=<a href='/topic/show?id=bbbfe98944d' target=_blank style='color:#2F92EE;'>#美国获批#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79894, encryptionId=bbbfe98944d, topicName=美国获批)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Dec 04 00:57:00 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341131, encodeId=bb801341131ef, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2235, encryptionId=b97e223562, topicName=AKI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346299, encodeId=3234134629909, content=<a href='/topic/show?id=339e8332035' target=_blank style='color:#2F92EE;'>#胃肠道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83320, encryptionId=339e8332035, topicName=胃肠道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378547, encodeId=e25d13e85471a, content=<a href='/topic/show?id=2cf09992871' target=_blank style='color:#2F92EE;'>#靶向疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99928, encryptionId=2cf09992871, topicName=靶向疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b676418, createdName=yanghan, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426027, encodeId=b460142602e01, content=<a href='/topic/show?id=02fe9e30227' target=_blank style='color:#2F92EE;'>#间质瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97302, encryptionId=02fe9e30227, topicName=间质瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ede4029724, createdName=zhty5338, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467511, encodeId=6265146e511e5, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585480, encodeId=2709158548033, content=<a href='/topic/show?id=f19310515b9' target=_blank style='color:#2F92EE;'>#KIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10515, encryptionId=f19310515b9, topicName=KIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8ff17204571, createdName=shuangle, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1780389, encodeId=c7551e8038984, content=<a href='/topic/show?id=bafd3539de' target=_blank style='color:#2F92EE;'>#Blueprint#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3539, encryptionId=bafd3539de, topicName=Blueprint)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4902500082, createdName=1249883fm12暂无昵称, createdTime=Thu Jan 16 15:57:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780263, encodeId=ae3f1e8026309, content=<a href='/topic/show?id=e7ea30e206' target=_blank style='color:#2F92EE;'>#Ayvakit#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3072, encryptionId=e7ea30e206, topicName=Ayvakit)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Tue Sep 01 04:57:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923730, encodeId=9f6a1923e30d2, content=<a href='/topic/show?id=093b353eed' target=_blank style='color:#2F92EE;'>#blue#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3537, encryptionId=093b353eed, topicName=blue)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Thu Mar 26 17:57:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807401, encodeId=834f180e4014c, content=<a href='/topic/show?id=bbbfe98944d' target=_blank style='color:#2F92EE;'>#美国获批#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79894, encryptionId=bbbfe98944d, topicName=美国获批)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Dec 04 00:57:00 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341131, encodeId=bb801341131ef, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2235, encryptionId=b97e223562, topicName=AKI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346299, encodeId=3234134629909, content=<a href='/topic/show?id=339e8332035' target=_blank style='color:#2F92EE;'>#胃肠道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83320, encryptionId=339e8332035, topicName=胃肠道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378547, encodeId=e25d13e85471a, content=<a href='/topic/show?id=2cf09992871' target=_blank style='color:#2F92EE;'>#靶向疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99928, encryptionId=2cf09992871, topicName=靶向疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b676418, createdName=yanghan, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426027, encodeId=b460142602e01, content=<a href='/topic/show?id=02fe9e30227' target=_blank style='color:#2F92EE;'>#间质瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97302, encryptionId=02fe9e30227, topicName=间质瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ede4029724, createdName=zhty5338, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467511, encodeId=6265146e511e5, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585480, encodeId=2709158548033, content=<a href='/topic/show?id=f19310515b9' target=_blank style='color:#2F92EE;'>#KIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10515, encryptionId=f19310515b9, topicName=KIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8ff17204571, createdName=shuangle, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1780389, encodeId=c7551e8038984, content=<a href='/topic/show?id=bafd3539de' target=_blank style='color:#2F92EE;'>#Blueprint#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3539, encryptionId=bafd3539de, topicName=Blueprint)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4902500082, createdName=1249883fm12暂无昵称, createdTime=Thu Jan 16 15:57:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780263, encodeId=ae3f1e8026309, content=<a href='/topic/show?id=e7ea30e206' target=_blank style='color:#2F92EE;'>#Ayvakit#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3072, encryptionId=e7ea30e206, topicName=Ayvakit)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Tue Sep 01 04:57:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923730, encodeId=9f6a1923e30d2, content=<a href='/topic/show?id=093b353eed' target=_blank style='color:#2F92EE;'>#blue#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3537, encryptionId=093b353eed, topicName=blue)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Thu Mar 26 17:57:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807401, encodeId=834f180e4014c, content=<a href='/topic/show?id=bbbfe98944d' target=_blank style='color:#2F92EE;'>#美国获批#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79894, encryptionId=bbbfe98944d, topicName=美国获批)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Dec 04 00:57:00 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341131, encodeId=bb801341131ef, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2235, encryptionId=b97e223562, topicName=AKI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346299, encodeId=3234134629909, content=<a href='/topic/show?id=339e8332035' target=_blank style='color:#2F92EE;'>#胃肠道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83320, encryptionId=339e8332035, topicName=胃肠道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378547, encodeId=e25d13e85471a, content=<a href='/topic/show?id=2cf09992871' target=_blank style='color:#2F92EE;'>#靶向疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99928, encryptionId=2cf09992871, topicName=靶向疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b676418, createdName=yanghan, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426027, encodeId=b460142602e01, content=<a href='/topic/show?id=02fe9e30227' target=_blank style='color:#2F92EE;'>#间质瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97302, encryptionId=02fe9e30227, topicName=间质瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ede4029724, createdName=zhty5338, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467511, encodeId=6265146e511e5, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585480, encodeId=2709158548033, content=<a href='/topic/show?id=f19310515b9' target=_blank style='color:#2F92EE;'>#KIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10515, encryptionId=f19310515b9, topicName=KIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8ff17204571, createdName=shuangle, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=)]
    2020-01-12 syscxl
  10. [GetPortalCommentsPageByObjectIdResponse(id=1780389, encodeId=c7551e8038984, content=<a href='/topic/show?id=bafd3539de' target=_blank style='color:#2F92EE;'>#Blueprint#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3539, encryptionId=bafd3539de, topicName=Blueprint)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4902500082, createdName=1249883fm12暂无昵称, createdTime=Thu Jan 16 15:57:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780263, encodeId=ae3f1e8026309, content=<a href='/topic/show?id=e7ea30e206' target=_blank style='color:#2F92EE;'>#Ayvakit#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3072, encryptionId=e7ea30e206, topicName=Ayvakit)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Tue Sep 01 04:57:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923730, encodeId=9f6a1923e30d2, content=<a href='/topic/show?id=093b353eed' target=_blank style='color:#2F92EE;'>#blue#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3537, encryptionId=093b353eed, topicName=blue)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Thu Mar 26 17:57:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807401, encodeId=834f180e4014c, content=<a href='/topic/show?id=bbbfe98944d' target=_blank style='color:#2F92EE;'>#美国获批#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79894, encryptionId=bbbfe98944d, topicName=美国获批)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Fri Dec 04 00:57:00 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341131, encodeId=bb801341131ef, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2235, encryptionId=b97e223562, topicName=AKI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346299, encodeId=3234134629909, content=<a href='/topic/show?id=339e8332035' target=_blank style='color:#2F92EE;'>#胃肠道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83320, encryptionId=339e8332035, topicName=胃肠道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378547, encodeId=e25d13e85471a, content=<a href='/topic/show?id=2cf09992871' target=_blank style='color:#2F92EE;'>#靶向疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99928, encryptionId=2cf09992871, topicName=靶向疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b676418, createdName=yanghan, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426027, encodeId=b460142602e01, content=<a href='/topic/show?id=02fe9e30227' target=_blank style='color:#2F92EE;'>#间质瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97302, encryptionId=02fe9e30227, topicName=间质瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ede4029724, createdName=zhty5338, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467511, encodeId=6265146e511e5, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585480, encodeId=2709158548033, content=<a href='/topic/show?id=f19310515b9' target=_blank style='color:#2F92EE;'>#KIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10515, encryptionId=f19310515b9, topicName=KIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8ff17204571, createdName=shuangle, createdTime=Sun Jan 12 06:57:00 CST 2020, time=2020-01-12, status=1, ipAttribution=)]
    2020-01-12 shuangle